# FinalDose

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/finaldose

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: finaldose.ai
- Latest round: Seed (Jun 2, 2026)
- Investors on record: 2

## About

FinalDose is a biotechnology firm dedicated to developing innovative cancer therapy solutions that utilize advanced DNA targeting and programmable delivery mechanisms to enhance treatment efficacy while safeguarding healthy tissues.FinalDose, founded in 2025 and headquartered in San Francisco, US, specializes in biotechnology focused on cancer therapies. The company has completed a single funding deal, attracting investments to bolster its operations. The most recent deal occurred on June 2, 2026, where FinalDose raised an undisclosed amount of Seed funding from Pioneer Fund and Y Combinator. The founder's history is not publicly documented, and there are no known pivots or changes in business strategy.FinalDose specializes in advanced cancer therapy solutions, focusing on a comprehensive architecture that leverages DNA targeting, programmable delivery, and elimination mechanisms to address various forms of cancer. The company’s core product offerings are designed to precisely target cancer cells while minimizing damage to healthy tissues, thereby enhancing therapeutic efficacy and patient safety. Their solutions are aimed at healthcare providers, oncology clinics, and research institutions, with an emphasis on customizable treatments that can be tailored to individual patient profiles. FinalDose's therapeutic products are being marketed in North America and Europe, where demand for innovative cancer therapies is growing rapidly due to increasing cancer prevalence and the need for more efficient treatment options.FinalDose generates revenue primarily through direct partnerships with oncology clinics and healthcare providers, facilitating the distribution of their cancer therapy solutions. The company's transactional structure involves B2B engagements, where healthcare institutions purchase therapies on a per-patient basis or through subscription models that allow for ongoing access to their technology. The company offers a range of products, including flagship therapies that have been designed for specific cancer treatments. Pricing structures are determined based on the complexity and customization of the therapies, ensuring that clients receive tailored solutions for their patient populations. This strategic pricing approach supports FinalDose's goal of making advanced cancer therapies accessible to a diverse range of healthcare settings.FinalDose plans to leverage the Seed funding raised in June 2026 to accelerate its growth initiatives. The company is focused on developing new cancer therapies and will strategically expand into additional markets, including Europe and Asia, by 2027. This expansion aims to increase the accessibility of their innovative therapeutic solutions in response to the growing global demand.

## Funding rounds

- Seed, Jun 2, 2026 — Y Combinator, Pioneer Fund

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed